Working… Menu

Familial Cancer Registry and DNA Bank

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02083224
Recruitment Status : Unknown
Verified March 2014 by Haematology-Oncology, National University Hospital, Singapore.
Recruitment status was:  Recruiting
First Posted : March 11, 2014
Last Update Posted : March 11, 2014
Information provided by (Responsible Party):
Haematology-Oncology, National University Hospital, Singapore

Brief Summary:

Clinical cancer genetics is an emerging new field in medical oncology, and has been incorporated into routine oncology practice in many leading medical institutions in North America and Europe. Cancer genetics is the study of genetic factors contributing to carcinogenesis. In the last 5-10 years, genes responsible for various well-defined hereditary cancer syndromes have been cloned. These include the BRCAJ/2 genes in hereditary breast and ovarian cancer syndrome, the A4PC gene in Familial Adenomatous Polyposis, and the mismatch repair genes (hMLH1, hMSH2, hPMS1, hPMS2, hMSH6) in hereditary non-polyposis colorectal cancer (HNPCC). One of the goals of a clinical cancer genetics service is to identify families at risk for hereditary cancer syndromes, provide genetic counseling, and offer genetic testing when appropriate. The identification of causative genes in hereditary cancer syndromes together with the advent of genetic testing is starting to have an impact on clinical management. The ability to identify a gene mutation in a cancer family allows predictive testing, stratifying at-risk family members into carriers who will benefit from aggressive surveillance and/or preventive options, and non-carriers who may be spared unnecessary surveillance. Appropriate use of genetic testing will ultimately result in medical cost reduction.

The investigators hypothesize that the clinical characteristics and genetic factors contributing to hereditary cancer in the Singaporean Asian population are distinct from those described for Western patients.

Condition or disease

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 2000 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 5 Years
Official Title: Familial Cancer Registry and DNA Bank
Study Start Date : January 2000
Estimated Primary Completion Date : December 2018

Cancer patients

Primary Outcome Measures :
  1. Change in genetics testing method [ Time Frame: 2 years ]

Biospecimen Retention:   Samples With DNA
Blood for DNA banking and future genotyping Questionnaires regarding family history of cancer and personal medical history will be taken.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   13 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients are recruited from the National University Hospital. All cancer patients seen in the Cancer Centre, NUH, are screened using a basic family history form.The family history is reviewed by the Principal Investigator with the cancer genetics counselor. Eligible patients who fulfil the eligibility criteria as described below are invited to participate. Written informed consent is obtained. Demographic characteristics and cancer history of the study subject is prospectively recorded. Participants are invited to fill out a family history questionnaire providing cancer history information on their first- and second-degree relatives. Participants are also invited to donate 10ml blood for DNA banking and future genotyping. Permission will be obtained from participants to contact family members who may be eligible to participate in the study.

Inclusion Criteria:

  • Any individual with very early onset cancer (eg diagnosed before age 40).
  • Any family with three or more first- or second-degree relatives with the same cancer
  • Any individual with two or more different primary cancers
  • Any family that fulfils diagnostic criteria for known hereditary cancer syndromes

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02083224

Layout table for location contacts
Contact: Soo Chin Lee, MBBS, MRCP +65 6779 5555

Layout table for location information
National University Hospital Recruiting
Singapore, Singapore, 119074
Contact: Soo Chin Lee, MBBS, MRCP    +65 6779 5555   
Sponsors and Collaborators
National University Hospital, Singapore
Layout table for investigator information
Principal Investigator: Soo Chin Lee, MBBS, MRCP National University Hospital, Singapore
Additional Information:

Layout table for additonal information
Responsible Party: Haematology-Oncology, Lee Soo Chin, National University Hospital, Singapore Identifier: NCT02083224    
Other Study ID Numbers: 2000/00511
First Posted: March 11, 2014    Key Record Dates
Last Update Posted: March 11, 2014
Last Verified: March 2014